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Abstract
Probably the foremost hypothesis of depression is the 5-hydroxytryptamine (5-HT, serotonin)
deficiency hypothesis. Accordingly, anomalies in putative 5-HT biomarkers have repeatedly been
reported in depression patients. However, whether such anomalies in fact reflect deficient central
5-HT neurotransmission remains unresolved. We employed a naturalistic model of 5-HT
deficiency, the tryptophan hydroxylase 2 (Tph2) R439H knockin mouse, to address this question.
We report that Tph2 knockin mice have reduced basal and stimulated levels of extracellular 5-HT
(5-HTExt). Interestingly, cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA) and
fenfluramine-induced plasma prolactin levels are markedly diminished in the Tph2 knockin mice.
These data seemingly confirm that low CSF 5-HIAA and fenfluramine-induced plasma prolactin
reflects chronic, endogenous central nervous system (CNS) 5-HT deficiency. Moreover, 5-HT1A
receptor agonist-induced hypothermia is blunted and frontal cortex 5-HT2A receptors are increased
in the Tph2 knockin mice. These data likewise parallel core findings in depression, but are usually
attributed to anomalies in the respective receptors rather than resulting from CNS 5-HT
deficiency. Further, 5-HT2A receptor function is enhanced in the Tph2 knockin mice. In contrast,
5-HT1A receptor levels and G-protein coupling is normal in Tph2 knockin mice, indicating that
the blunted hypothermic response relates directly to the low 5-HTExt. Thus, we show that not only
low CSF 5-HIAA and a blunted fenfluramine-induced prolactin response, but also blunted 5-HT1A
agonist-induced hypothermia and increased 5-HT2A receptor levels are bona fide biomarkers of
chronic, endogenous 5-HT deficiency. Potentially, some of these biomarkers could identify
patients likely to have 5-HT deficiency. This could have clinical research utility or even guide
pharmacotherapy.
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Chronic, endogenous 5-hydroxytryptamine (5-HT, serotonin) deficiency has been
prominently implicated in the etiology of depression for over 40 years. The hypothesis
originally derived from the clinical observation that drugs enhancing 5-HT
neurotransmission, by inhibiting the serotonin-reuptake transporter (SERT) or monoamine
oxidase (MAO), displayed antidepressant activity.1 However, that enhancing 5-HT function
alleviates depression does not necessarily mean that depression is caused by a primary 5-HT
deficit. It also remains an outstanding question whether depression is accompanied, or can
be caused, by central nervous system (CNS) 5-HT deficiency, although it should be noted
that decreased midbrain 5-HT levels have been reported in depressed suicide victims.2
Unfortunately, this question is difficult to address since brain extracellular 5-HT (5-HTExt,
the functionally active pool acting at 5-HT receptors) cannot currently be assessed in
humans.3 In lieu of direct measures, aberrations of putative biomarkers of central 5-HT
neurotransmission in depression and other psychiatric disorders have been interpreted as
reflecting CNS 5-HT deficiency.4 Prominently, low cerebrospinal fluid (CSF) levels of 5-
hydroxyindoleacetic acid (5-HIAA, the main 5-HT metabolite)5 and a blunted plasma
prolactin response to the 5-HT releaser fenfluramine6,7 have repeatedly been reported in
depression, particularly when suicidality is present, and suggested to reflect CNS 5-HT
deficiency. Indeed, acute tryptophan depletion, a procedure that likely reduces CNS 5-
HTExt,8 produces reductions in both CSF 5-HIAA and fenfluramine-induced plasma
prolactin in healthy volunteers.9,10 However, starving the organism of the essential amino
acid tryptophan may well have numerous effects apart from lowering 5-HT. For instance,
tryptophan occurs in the amino acid chain of prolactin and is the precursor of the
endogenous glutamatergic/cholinergic receptor ligand kynurenic acid.11,12 Moreover, it is
not necessarily obvious that low CSF 5-HIAA and fenfluramine-induced plasma prolactin
would reflect a CNS 5-HT deficit. Often 5-HTExt and extracellular 5-HIAA dynamics do not
correlate,13,14 and prolactin secretion is regulated by a myriad of neurotransmitter systems
in addition to 5-HT, notably dopamine.15,16 Thus, whether low CSF 5-HIAA and/or blunted
fenfluramine-induced plasma prolactin reflects chronic endogenous CNS 5-HT deficiency
remains to be directly demonstrated.
Similarly, blunted hypothermic responses to 5-HT1A receptor (5-HT1AR) agonists17–19 and
increased levels of frontal cortex 5-HT2A receptors (5-HT2ARs)20–22 have repeatedly been
reported in depression and suicidality. The pathobiologies of such observations are not
known but are usually ascribed to anomalies in 5-HT1AR and 5-HT2AR function rather than
CNS 5-HT-deficiency per se. The mechanism of 5-HT1AR agonist-induced hypothermia is
poorly defined and the observation of a blunted response in depression is somewhat
counterintuitive. Chronic enhancement of 5-HTExt actually results in blunted 5-HT1AR
agonist-induced hypothermia via 5-HT1AR autoreceptor desensitization.13,23–25 Reduced
extracellular levels of, for instance, dopamine can lead to increases in dopamine receptors.26
A similar causal relationship could be envisioned for 5-HTExt and 5-HT2AR. However, it is
not given a priori that increased 5-HT2ARs would result from CNS 5-HT deficiency in
depression. For instance, pharmacological 5-HT depletion in rats has inconsistent effects on
5-HT2AR levels.27,28 Moreover, reduced 5-HT1ARs have been reported in depression.29,30
We investigated whether chronic, endogenous 5-HT deficiency results in aberrations in
putative CNS 5-HT biomarkers as reported in depression. To this end, we employed a
naturalistic mouse model of 5-HT deficiency, the tryptophan hydroxylase 2 (Tph2) R439H
knockin mouse.31 This murine model harbors a single point mutation producing a R439H
substitution in Tph2, the rate-limiting enzyme in brain 5-HT synthesis.31 The analogous
human mutation, R441H, was originally identified in a late life depression cohort.32 Tph2
R439H mice (Tph2 knockin mice henceforth) have markedly reduced 5-HT synthesis and
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tissue levels and exhibit increased depression-, anxiety- and aggression-like behaviors.31
Here, we report that Tph2 knockin mice have robustly reduced 5-HTExt levels and dynamics
that are accompanied by a depression-like putative 5-HT biomarker profile: low CSF 5-
HIAA, reduced fenfluramine-induced plasma prolactin, a blunted 5-HT1AR agonist
hypothermic response and increased frontal cortex 5-HT2ARs.
Subjects and methods
Animals
The generation of the Tph2 knockin mice has been described previously.31 Littermate mice
were housed 3–5 per cage with food and water available ad libitum on a 12-h light–dark
cycle at an ambient temperature of 21±2 °C. Unless noted, experiments were conducted
during the light phase. All experiments used age- and gender-matched wild type (WT) and
Tph2 knockin littermate mice (3–6 months old) maintained on a mixed 129S6/SvEv ×
C57BL/6J background (see Supplementary Table 1 for gender distribution within groups).
Experiments were conducted in accordance with the National Institutes of Health guidelines
for the care and use of animals and an approved animal protocol from the Duke University
Animal Care and Use Committee.
Materials
Escitalopram was a generous gift from Lundbeck (Valby, Denmark). Dexfenfluramine, 8-
OH-DPAT, DOI, 5-HT, 5-hydroxytryptophan (5-HTP), 5-HIAA, 3,4-dihydroxyphenylacetic
acid, homovanillic acid and clonidine were purchased from Sigma (St Louis, MO, USA).
NAN-190 and DPCPX were purchased from Tocris (Ellisville, MO, USA). [125I]p-MPPI
was obtained from Perkin Elmer (Waltham, MA, USA). [3H]WAY100635, [3H]ketanserin,
[3H]citalopram and [35S]GTPγS were purchased from Perkin Elmer. All other reagents used
were of analytic grade. All drugs were administered in a volume of 10 ml kg−1 in saline,
intraperitoneal (i.p.) or subcutaneous (s.c.), as indicated.
Microdialysis
Surgery—Mice were anesthetized by ketamine/ xylazine (100 and 10 mg kg−1,
respectively, in saline, i.p) and a guide cannula (CMA7, CMA Microdialysis, Chelmsford,
MA, USA) was stereotactically implanted into the frontal cortex (AP: 2.3 mm, ML: 0.3 mm,
DV: 0.7 mm), hippocampus (AP: −3.3 mm, ML: 3.0 mm, DV: 1.5 mm) or lateral ventricle
(AP: 0.3 mm; ML: 0.9 mm; DV: 2.0 mm) according to the atlas by Franklin and Paxinos33
and fixed in place with two anchor screws (CMA) and carboxylate dental cement (CMA).
Operated mice were singly housed, treated with antibiotics (1.2 mg sulfamethoxazole ml−1
and 0.24 mg trimethoprim ml−1) in the drinking water and allowed to recover 48–96 h post-
surgery.
Dialysate collection—The microdialysis probe was inserted into the guide cannula
approximately 16 h before the start of sample collection to allow for the stabilization of 5-
HTExt levels. It has been previously demonstrated that dialysate analyte levels are usually
only influenced by the tissue trauma caused by probe insertion for a few hours and that the
blood–brain barrier is usually not compromised in brain microdialysate experiments.34
However, we employed a relatively long (overnight) stabilization period to ensure that we
reached stable baseline 5-HTExt levels unaffected by peripheral (that is, Tph1 derived) 5-
HT. In confirmation of the neuronal origin of the dialysate 5-HT, the 5-HT1AR agonist 8-
OH-DPAT (1 mg kg−1, i.p.) decreased 5-HTExt by approximately 50% (Supplementary
Figure S1), a decrement that is within the range typically reported after 8-OH-DPAT
administration.23,35 The mouse was gently restrained and the microdialysis probe (CMA7
7/2 for frontal cortex and hippocampus, CMA7 7/1 for lateral ventricle) was inserted into the
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guide cannula. The mouse was then placed in a circular chamber with bedding, chow and
water available. A two-channel swivel (cat. no. 375/D/22QM; Instech, Plymouth Meeting,
PA, USA) allowed for unimpeded movement of the mouse. Artificial CSF (147 mM NaCl,
2.7 mM KCl, 0.85 mM MgCl2, 1.2 mM CaCl2, CMA) was delivered at a flow rate of 0.45
μl min−1 from probe insertion until the end of experiment. Following the stabilization
period, samples (30- or 120-min sample duration, as noted) were collected on ice in the
dark, immediately frozen on dry ice and stored at −80 °C. Dialysates were analyzed off-line
by high-performance liquid chromatography-electrochemical detection (HPLC-EC, see
Supplementary Methods) for 5-HT, 5-HIAA, 3,4-dihydroxyphenylacetic acid and
homovanillic acid, or by the SymDAQ HPLC-tandem-mass spectrometry technology (see
Supplementary Methods) for simultaneous determination of monoamines and amino acids.
Microdialysis experiment 1—In all mice, 120-min dialysates were collected at zeitgeber
noon or midnight from frontal cortex or hippocampus. A 22.5 μl aliquot of each dialysate
was transferred to 7.5 μl 20 mM formic acid. This sample was used for monoamine and
amino acid analysis by SymDAQ HPLC-tandem-mass spectrometry. The remaining
dialysate was used for 5-HT analysis using HPLC-EC. Thereafter, the following noon, two
30-min baseline dialysates were collected and then KCl raised to 100 mM in the artificial
CSF to produce neuronal depolarization proximal to the probe membrane via reverse
dialysis and four more dialysates collected.
Microdialysis experiment 2—Dialysates were collected from either frontal cortex or
hippocampus. One 30-min baseline dialysate was collected followed by escitalopram (10 mg
kg−1, i.p., 10 ml mg−1 in saline) injection and four more dialysates collected. 5-HT was
analyzed by HPLC-EC (see Supplementary Methods).
Microdialysis experiment 3—The probe membrane was placed in the lateral ventricle to
collect CSF. One 30-min sample was collected at noon. 5-HIAA was analyzed by HPLC-EC
(see Supplementary Methods).
Tissue 5-HT and 5-HIAA analysis
Frontal cortex and hippocampus were rapidly dissected and frozen on dry ice. Tissues were
homogenized by sonication in 20 volumes of ice-cold 100 mM HClO4. The supernatants
were recovered and passed through 0.2 μm filters and 5-HT and 5-HIAA quantified in the
filtrates by HPLC-EC (see Supplementary Methods).
Marble burying
The mouse was introduced into a novel arena (25 × 36 cm; height: 18 cm) with 24 marbles
latticed on top of four inches of lightly compressed aspen wood shavings. After 30 min, the
mouse was removed, a photograph taken from above and the number of marbles still visible
on the photograph counted by an observer blind to the genotype. Marbles buried = 24 minus
number of visible marbles.
Plasma prolactin and corticosterone
For assessment of naïve/diurnal plasma prolactin and corticosterone, unhandled mice were
transferred from the holding room to an adjacent room, rapidly decapitated and trunk blood
collected in EDTA-coated tubes. Such plasma samples were collected at zeitgeber time 0
and 12 h. For the response to dexfenfluramine (10 mg kg−1, i.p.), mice were killed and
plasma samples collected as described above 60 min after saline or dexfenfluramine
administration. Plasma prolactin levels were determined by an enzyme-linked
immunosorbent assay kit according to the manufacturer’s instructions (GenWay Biotech,
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San Diego, CA, USA) and corticosterone levels were determined using a competitive
binding enzyme immunoassay kit according to the manufacturer’s instructions (Assay
Designs, Ann Arbor, MI, USA).
5-HT1AR agonist-induced hypothermia
The 5-HT1AR or α2R agonist-induced hypothermic response was assessed as described.36 In
brief, following an initial conditioning rectal probe insertion, three baseline body
temperature readings were recorded with 15-min intervals using a digital rectal probe
thermometer. Thereafter, 8-OH-DPAT (1 mg kg−1, i.p.) or clonidine (0.2 mg kg−1, i.p.) was
injected and six additional readings recorded.
5-HT2AR mediated head-twitches/head-shakes
Three different pharmacological manipulations were employed to induce head-twitches/
head-shakes. These behaviors are part of the complex syndrome induced by supranormal 5-
HT neurotransmission and are mainly mediated by 5-HT2ARs.37 The number of head-
twitches or head-shakes was scored from 1-min videos by an observer blind to time,
treatment and genotype.
Head-twitches induced by combined MAO A and SERT inhibition
Under these conditions, where 5-HT breakdown and reuptake is simultaneously blocked, the
head-twitch response will closely relate to Tph2 enzymatic activity. Clorgyline (10 mg kg−1,
i.p.) was injected immediately after recording the initial video. Sixty min later, the second
video was recorded and then escitalopram (10 mg kg−1, s.c.) was injected. Hereafter videos
were recorded of each animal every 30 min for 150 min.
Head-twitches induced by combined 5-HTP administration and SERT inhibition
5-HTP is the enzymatic product of Tph2. Hence, the head-twitch response is expected to be
largely de-coupled from Tph2 enzymatic activity under these conditions. 5-HTP (100 mg
kg−1, i.p.) and escitalopram (10 mg kg−1, s.c.) were injected immediately after recording the
initial video. Hereafter videos were recorded every 30 min for 150 min.
Head-shakes induced by DOI
Here the head-shakes response is induced by direct 5-HT2AR stimulation by the 5-HT2A/CR
agonist DOI. DOI (3 mg kg−1, i.p.) was injected immediately after recording the initial video
and hereafter videos were recorded every 30 min for 90 min.
Ligand saturation binding of 5-HT1AR, 5-HT2AR and SERT in brain tissue
[3H]WAY100635, [3H]ketanserin and [3H]citalopram were used for 5-HT1AR, 5-HT2AR
and SERT binding, respectively. Saturation binding was performed on rapidly dissected
tissues stored at −80 °C until used, employing standard protocols (see Supplementary
Methods).
5-HT1AR autoradiography
Mice were quickly euthanized by cervical dislocation and the brains collected and rapidly
frozen on dry ice. In all, 20 μm cryo-sections were cut at the level of the hippocampus/
hypothalamus and dorsal raphe, −2.06 and −4.5 mm relative to Bregma,33 respectively, onto
silanized microscope slides. The sections were desiccated at 4 °C overnight and stored at
−80 °C. [125I]p-MPPI binding for quantitation of 5-HT1AR levels and [35S]GTPγS binding
for assessment of 5-HT1AR G-protein coupling were performed using standard
protocols38,39 (see Supplementary Methods).
Jacobsen et al. Page 5











Data were analyzed with unpaired Student’s t-test, two-way analysis of variance (ANOVA)
or two-way repeated measures (RM)-ANOVA using Prism statistical software version 5.0c
(GraphPad Software, La Jolla, CA, USA). When significant factor effects or factor
interactions were detected, analysis of variances were followed by Bonferroni post hoc
analysis. Data are presented as mean±s.e.m.
Results
To assess 5-HTExt levels in the Tph2 knockin mice, we employed microdialysis and
documented that basal 5-HTExt levels are decreased by more than half in both the frontal
cortex and hippocampus (Figures 1b and f), two regions believed to be functionally
compromised in depression.40 Evoked neuron terminal 5-HT release induced by either K+
depolarization (Figures 1c and g) or a selective serotonin reuptake inhibitor (SSRI; Figures
1d and h) was preserved but markedly attenuated in the Tph2 knockin mice. This attests to a
loss, but not absence, of central 5-HT function. SSRIs decrease marble burying in mice with
remarkable reliability across reports.41 In fact, mouse marble burying behavior has been
reported to show a close, inverse relationship to frontal 5-HTExt levels.42,43 This indicates
that marble burying could represent a functional reflection of frontal cortex 5-HTExt levels,
with increased 5-HTExt levels yielding decreased marble burying and decreased 5-HTExt
levels yielding increased marble burying. Hence, we hypothesized that 5-HT deficiency in
the Tph2 knockin mice would cause these mice to bury more marbles. Indeed, that is what
we observed (Figure 1i), indicating that the observed frontal 5-HTExt decrement in the
knockin mice has direct functional sequelae. Conversely, acutely increasing 5-HTExt levels
by treatment with the SSRI escitalopram (10 mg kg−1, i.p.) or the 5-HT precursor 5-HTP (50
mg kg−1, i.p.) robustly decreased marble burying in both WT and Tph2 knockin mice
(Supplementary Figure S2). Similar to data obtained from adult mice (Figure 1j)31 tissue
levels of 5-HT and 5-HIAA were markedly reduced in frontal cortex and hippocampus from
neonatal mice (P2; Figure 1k). Thus, endogenous 5-HT neurotransmission is reduced, but
not abolished, in the Tph2 knockin mice and this state appears to be present from birth.
To determine whether chronic endogenous 5-HTExt deficiency is reflected in reduced CSF
5-HIAA, we collected CSF by microdialysis and found that Tph2 knockin mice have CSF 5-
HIAA levels < 10% of WT mice (Figure 2a). The size of this decrement is within the range
reported in suicidal individuals.44 In contrast, CSF levels of the dopamine metabolites 3,4-
dihydroxyphenylacetic acid and homovanillic acid were unchanged in the knockin mice
(Figure 2e). Next, we injected WT and knockin mice with saline or dexfenfluramine (the
active fenfluramine enantiomer) and collected plasma 60 min later. In WT mice
dexfenfluramine robustly increased plasma prolactin while no changes were seen in Tph2
knockin mice (Figure 2b). A similarly blunted prolactin response to fenfluramine has been
reported in for instance suicidal depression inpatients.45 There were no genotype differences
in plasma prolactin in naïve or saline treated mice (Figure 2b). Similarly, diurnal trough and
peak levels of prolactin were unchanged in Tph2 knockin mice (Figure 2f), attesting to
normal diurnal prolactin secretion. Plasma corticosterone at diurnal trough and peak or
following dexfenfluramine administration did not differ between genotypes (Supplementary
Figure S3). Next, we investigated the hypothermic response to the 5-HT1AR agonist 8-OH-
DPAT. In the Tph2 knockin mice, the core body temperature drop was markedly attenuated
compared with WT (Figure 2c). These data mirror clinical studies reporting markedly
attenuated 5-HT1AR-induced hypothermic responses in unmedicated depression
inpatients.17,18 In contrast, the hypothermic response to the α2 receptor agonist clonidine
was preserved and even enhanced in the Tph2 knockin mice (Figure 2g). The hyperthermic
response to rectal probe insertion (stress-induced hyperthermia46) was likewise preserved
(Supplementary Figure S4), further demonstrating that thermo-regulation is not generally
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impaired in the Tph2 knockin mice. Next, we investigated 5-HT2AR levels in the frontal
cortex using radioligand saturation binding and found a 23% increase in the Tph2 knockin
mice (Figure 2d). A frontal cortex 5-HT2AR increase of similar magnitude has been reported
postmortem in suicide victims.20 A general upregulation of 5-HT receptors in the Tph2
knockin mice did not seem to occur because 5-HT1AR levels were unchanged in the
hippocampus (Figures 2h and 3e) as well as in the dorsal raphe and hypothalamus (Figure
3e).
Supranormal 5-HTExt can elicit quantifiable 5-HT syndrome-like behaviors in rodents,
including 5-HT2AR-dependent head-twitches and head-shakes.37 Co-administration of the
MAO A inhibitor clorgyline and the SSRI escitalopram simultaneously abolishes 5-HT
degradation and active extracellular clearance (passive clearance via diffusion remains).
This condition presumably creates a state where 5-HTExt levels and 5-HT receptor
occupancy more directly reflect Tph2 activity. Hence, as would be predicted given the
reduced Tph2 activity in the knockin mice,31 the head-twitch response to clorgyline +
escitalopram in Tph2 knockin mice was markedly attenuated (Figure 3a). Interestingly,
however, when Tph2 was bypassed by administering its enzymatic product, the 5-HT
precursor 5-HTP, together with escitalopram the head-twitch response was markedly
enhanced in the Tph2 knockin mice (Figure 3b). The latter finding signifies increased frontal
cortex 5-HT2AR function in the Tph2 knockin mice, in accord with the increased frontal
cortex 5-HT2AR levels (Figure 2d). This notion was further corroborated by the observation
that the Tph2 knock-in mice displayed exaggerated head-shake responses after injection of
DOI, a direct 5-HT2A/2CR agonist (Figure 3c).
Somatic 5-HT1ARs in the dorsal raphe have a key role in negative feedback control of 5-HT
release47 and hippocampal postsynaptic 5-HT1ARs may be important for SSRI
antidepressant responses.48 Further, evidence implicates the hypothalamus as the locus
mediating 5-HT1AR agonist hypothermia.13 Conceivably, 5-HT1AR signaling in these
regions could be compensatorily altered in the Tph2 knockin mice. In fact, the reduced 5-
HT1AR agonist hypothermic response in depression has been suggested to be caused by
impaired 5-HT1AR function.49 We therefore assessed regional 5-HT1AR levels and G-
protein coupling by parallel [125I]p-MPPI radioligand and 5-HT1AR agonist-stimulated
[35S]GTPγS binding auto-radiography, respectively, in the dorsal raphe, hippocampal CA1
region and the hypothalamus. We found that Tph2 knockin mice displayed WT levels of 5-
HT1ARs and G-protein coupling in all three regions (Figures 3d and e). This indicates no
compensations in 5-HT1AR function in the Tph2 knockin mice. Similarly, neither SERT
levels (Supplementary Figure S5) nor MAO mRNA expression or enzymatic activity in the
frontal cortex or hippocampus (Supplementary Figure S6) were changed in the Tph2
knockin mice.
Finally, extensive crosstalk between 5-HT and other monoamine and amino acid
neurotransmitters have been previously reported.50–52 It could therefore be hypothesized
that 5-HT deficiency would affect extracellular levels of monoamine and amino acid
neurotransmitters. We used the sensitive SymDAQ HPLC-tandem-mass spectrometry
technology53 that allows the simultaneous determination of 5-HTExt, dopamineExt,
noradrenalineExt, GABAExt, glycineExt and glutamateExt in microdialysates from frontal
cortex and hippocampus. We replicated the marked decrease in 5-HTExt at noon and
midnight in the Tph2 knockin mice (Figures 4a and g) determined using HPLC-EC (Figures
1b and f). Remarkably, however, no other neurotransmitter assessed was significantly
altered, at either time point or brain region (Figures 4b–f and h–l). This indicates that at least
under basal conditions 5-HT deficiency has no major effects on extracellular homeostasis of
the monoamines and amino acid neurotransmitters assessed. Still, the enhanced hypothermic
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response to clonidine in the Tph2 knockin mice seems to suggest that 5-HT deficiency leads
to changes in some noradrenergic responses.
Discussion
The present report contains two major findings. First, we demonstrate for the first time that a
polymorphism in the tph2 gene affects 5-HT neurotransmission, as assessed by 5-HTExt.
This finding is important and could extrapolate to other tph2 polymorphisms. Although the
human R441H analogue of the mouse R439H polymorphism is probably rare54 a number of
distinct polymorphisms in tph2 have been associated with psychopathology, including
depression.55–61 We found no evidence of compensatory changes in SERT, MAO and
somatic 5-HT1ARs, major regulatory elements of 5-HT neurotransmission. Our data
therefore suggest that loss-of-function mutations in Tph2 may not be significantly offset by
homeostatic mechanisms and that brain 5-HT neurotransmission is susceptible to impaired
Tph2 function. Studying hypomorphic murine models, particularly when induced by
introduction of naturally occurring polymorphisms, may have an advantage over knock-out
approaches because a level of functionality is preserved. Arguably, this provides a more
naturalistic deficit model with greater translational potential. Although the 5-HT deficiency
in this study was a consequence of Tph2 hypofunction, the current findings could potentially
extrapolate to 5-HT deficiency stemming from a variety of primary causes, for instance
reduced brain uptake of tryptophan, storage of 5-HT or decreased 5-HT neuronal firing.
A second, and perhaps even more salient finding, was the observation that chronic,
endogenous brain 5-HT deficiency results in reductions in CSF 5-HIAA, fenfluramine-
induced plasma prolactin and 5-HT1AR agonist-induced hypothermia in conjunction with
increased frontal cortex 5-HT2ARs. These findings in mice closely parallel findings in
depressed humans. Although low CSF 5-HIAA and a blunted prolactin response to
fenfluramine have long been suggested to reflect reduced central 5-HT levels4,6 until now
these notions had never actually been directly substantiated. On the other hand, the blunted
5-HT1AR agonist-induced hypothermia and increased frontal cortex 5-HT2ARs have rather
been ascribed to ‘abnormalities’ in 5-HT receptors in depression.20,49 We demonstrate here
that in fact also the two latter aberrations can arise as a result of chronic functional 5-HT
deficiency. Thus, our findings provide hitherto unavailable cause-effect evidence for all four
parameters as bona fide biomarkers of central 5-HT function. Importantly, the findings
corroborate the long-standing hypothesis of a central 5-HT deficit in depressive disorders,
particularly when suicidality is present.4–7,62
The most parsimonious explanations for the reduced CSF 5-HIAA and blunted
fenfluramine-induced prolactin response in the Tph2 knockin mice relates directly to the low
5-HT brain levels. Decreased 5-HT synthesis would yield low 5-HIAA formation, which
subsequently manifests as low CSF 5-HIAA. Decreased 5-HT storage would result in
blunted fenfluramine-induced 5-HT release and subsequently reduced 5-HT-mediated
prolactin secretion by pituitary lactotrophs, likely mediated by hypothalamic oxytonergic
and vasoactive intestinal peptidergic projection neurons from the hypothalamus.16 At first
glance, the blunted hypothermic response to the 5-HT1AR agonist 8-OH-DPAT in the 5-HT
deficient Tph2 knockin mice appears paradoxical. Specifically, a blunted hypothermic
response to a 5-HT1AR agonist resulting from enhancement of 5-HTExt levels via genetic or
pharmacological means is well documented.23,24 Downregulation of presynaptic 5-HT1AR
function seems unlikely because we found no changes in 5-HT1AR levels or G-protein-
coupling. This seeming lack of adaptation is hardly surprising since micro-dialysis studies
using 5-HT1AR antagonists indicate that there is little inhibitory signaling via presynaptic 5-
HT1ARs at baseline 5-HTExt levels.63,64 Still, we cannot completely rule out 5-HT1AR
signaling adaptations downstream of receptor expression and G-protein coupling. One report
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presented evidence that acute modulations in hypothalamic 5-HTExt levels regulate body
temperature with a direct, bidirectional relationship.13 However, another report did not find
this exact relationship.65 In turn, somatic 5-HT1AR autoreceptors in the raphe area appears
crucial in mediating the hypothermic response to 5-HT1AR agonists66,67 as well as the
apparently pan-CNS decrease in 5-HTExt induced by such ligands.25,68 It can therefore
reasonably be hypothesized that decreased baseline 5-HTExt levels could blunt the
hypothermic response to a 5-HT1AR agonist in the absence of any change in 5-HT1AR
function, namely by limiting the potential downward amplitude in Δ5-HTExt. Thus, low
baseline 5-HTExt levels per se could blunt the hypothermic response to a 5-HT1AR agonist,
though via a distinct mechanism than high baseline 5-HTExt levels. Still, further
examinations will be needed to delineate why low 5-HTExt levels cause blunted 5-HT1AR-
agonist hypothermia. Both 5-HT2ARs69,70 and 5-HT1ARs71 internalize upon ligand
binding.69,70 We found frontal cortex 5-HT2ARs, but not 5-HT1ARs in several regions,
upregulated in the Tph2 knockin mice. A tentative explanation for these differential
consequences of 5-HT deficiency on different receptor populations could pertain to
differential sensitivity in terms of receptor turnover to baseline levels of 5-HTExt. This
remains speculative, though. Moreover, for instance 5-HT2ARs beyond those in the frontal
cortex may respond differently to changes in ambient 5-HTExt levels. Although chronic
treatment with SSRIs can dramatically reduce brain SERT levels, MAO inhibitors do not
have this effect.72 This indicates that while SERT downregulates in response to SSRI
binding ambient 5-HTExt levels have little influence on SERT levels. Consistent with this
notion, we found no change in SERT levels in the frontal cortex and hippocampus of Tph2
knockin mice.
Several clinically efficacious antidepressants are antagonists of 5-HT2ARs.73 Further,
atypical antipsychotics with 5-HT2AR antagonistic activity are effective as add-on to SSRIs
in many treatment-resistant patients.74 It is therefore intriguing that 5-HT2AR levels and
function are increased in the Tph2 knockin mice as well as in at least some depression
populations.20,21 It could be cautiously speculated that 5-HT2AR hyperfunction in the frontal
cortex has a role in depression symptomatology.
The depression-related changes in 5-HT biomarkers reported here were found in Tph2
knockin mice that still maintain 25–40% of normal 5-HTExt levels. It would be relevant to
extend our findings by investigating whether a similar or even more dramatic 5-HT
biomarker phenotype might be present in Tph2 or Pet1 knockout mice that are almost
completely devoid of CNS 5-HT.75,76 Future studies clarifying the mechanisms for 5-HT
biomarker and behavioral31 changes in the Tph2 knockin mouse, or similar models of 5-HT
deficiency, may contribute to elucidating the neurobiology of affective disorders. In turn,
such investigations could ultimately point toward novel therapeutic targets. Further, 5-HT
biomarkers may have utility in a clinical research setting, if not in general practice.
Assessing 5-HT biomarkers, several of which are reasonably non-invasive, could assist in
determining whether sub-populations of psychiatric patients could selectively benefit from
5-HT augmentation strategies.
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Functional 5-hydroxytryptamine (5-HT) deficiency in tryptophan hydroxylase 2 (Tph2)
knockin mice. (a–d) Microdialysis, frontal cortex. (e–h) Microdialysis, hippocampus. (a, e)
Probe location in the frontal cortex and hippocampus. Vertical black bar indicates probe
membrane location. (Image modified from http://www.brain-map.org). (b, f) Basal
extracellular 5-HT (5-HTExt) at noon and midnight (N = 9–10). (c, g) Net 5-HTExt release
stimulated by reverse dialysis of 100 mM K+ via the probe (N = 8–10). (d, h) Net 5-HTExt
release stimulated by the selective serotonin reuptake inhibitor (SSRI) escitalopram (10 mg/
kg, i.p.) (N = 11–18). (i) Marbles buried in 30 min (N = 8–9). (k) Adult (12 weeks) tissue
levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) (N = 7–8). (j) Neonatal (P2) tissue
levels of 5-HT and 5-HIAA (N = 6–9). Data represent means±s.e.m. *P < 0.05 WT vs Tph2
knockin. (b–d, f–h) Repeated-measures (RM)-analysis of variance (ANOVA) followed by
Bonferroni post hoc test. (i–k) Student’s t-test.
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Alterations in putative 5-hydroxytryptamine (5-HT) biomarkers reported in depression and
suicidality are recapitulated in tryptophan hydroxylase 2 (Tph2) knockin mice. (a) Tph2
knockin mice have decreased cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-
HIAA) (N = 5–6), (b) a blunted prolactin response to dexfenfluramine (DexFen, 10 mg
kg−1, i.p., N = 6–9), (c) an attenuated hypothermic response to the 5-HT1A receptor (5-
HT1AR) agonist 8-OH-DPAT (1 mg kg−1, i.p., N = 10) and (d) increased frontal cortex 5-
HT2A receptors (5-HT2ARs) (N = 7). On the other hand, (e) Tph2 knockin mice have WT
levels of CSF 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and
of (f) plasma prolactin. (g) Tph2 knockin mice displayed a more pronounced hypothermic
response to the α2R agonist clonidine compared with WT. (h) Tph2 mice have WT levels of
5-HT1ARs in the hippocampus. Data represent means±s.e.m. (a, d, e, h) Student’s t-test. (b,
f) Two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. (c, g)
Repeated-measures (RM)-ANOVA followed by Bonferroni post hoc test. *P < 0.05 WT vs
Tph2 knockin. #P < 0.05 WT saline vs WT dexfenfluramine.
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5-Hydroxytryptamine2A receptors (5-HT2AR), but not 5-HT1A receptor (5-HT1AR), function
is altered in tryptophan hydroxylase 2 (Tph2) knockin mice. (a) Decreased head-twitches
induced by administration of clorgyline (10 mg kg−1, s.c.) 60 min before escitalopram (10
mg kg−1, i.p.), a Tph2 dependent condition, in Tph2 knockin mice (N = 10). (b) Increased
head-twitches induced by co-administration of 5-hydroxytryptophan (5-HTP) (100 mg kg−1,
s.c.) and escitalopram (10 mg kg, i.p.), a Tph2 independent condition, in Tph2 knockin mice
(N = 10). (c) Increased head shakes induced by the 5-HT2A/CR agonist DOI (3 mg kg−1,
i.p.), a Tph2 independent condition, in Tph2 knockin mice (N = 30–33). (d) Representative
autoradiograms and (e) quantitation of [125I]p-MPPI binding to 5-HT1ARs in the CA1 of the
hippocampus (left arrow), hypothalamus (HYP, middle arrow) and dorsal raphe (DR, right
arrow) (N = 8–10). (f) Representative autoradiograms and (g) quantitation of basal and 8-
OH-DPAT-stimulated [35S]GTPγS binding in CA1, hypothalamus and dorsal raphe (N = 7–
10). (a–c) Repeated-measures (RM)-analysis of variance (ANOVA) followed by Bonferroni
post hoc test. (d–g) Student’s t-test. *P < 0.05, WT vs Tph2 knockin. #P < 0.05, basal vs 8-
OH-DPAT treated, within genotype.
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Basal extracellular levels of dopamine, noradrenaline and amino acid neurotransmitters are
unchanged in tryptophan hydroxylase 2 (Tph2) knockin mice. (a–f) Frontal cortex (N = 7–
8). (g–l) Hippocampus (N = 9–10). (a, g) Extracellular 5-hydroxytryptamine (5-HTExt) was
decreased in Tph2 knockin mice. No significant genotype differences were found for any of
the other assessed neurotransmitters (b–f, h–l). Repeated-measures (RM)- analysis of
variance (ANOVA) followed by Bonferroni post hoc test. *P < 0.05 WT vs Tph2 knockin.
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